Parkinsons Disease Market

DelveInsight’s ‘Parkinson’s Disease (PD)– Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Parkinson’s Disease in the United States.


The Parkinson’s Disease market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Parkinson’s Disease market Size from 2018 to 2030 in the United States market. The report also covers the current Parkinson’s Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geography Covered

  • The United States

Study Period: 2018–2030

Parkinson’s Disease: Disease Understanding and Treatment Algorithm

Parkinson’s Disease Overview

American Association of Neurological Surgeons defines Parkinson’s Disease as a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine. Normally, dopamine operates in a delicate balance with other neurotransmitters to help coordinate the millions of nerve and muscle cells involved in the movement. Without enough dopamine, this balance is disrupted, resulting in tremor (trembling in the hands, arms, legs, and jaw), rigidity (stiffness of the limbs), slowness of movement, and impaired balance and coordination are hallmark symptoms of Parkinson’s Disease. People with Parkinson’s also lose the nerve endings that produce norepinephrine, the main chemical messenger of the sympathetic nervous system, which controls many automatic functions of the body, such as heart rate and blood pressure. The loss of norepinephrine might help explain some of the nonmovement features of Parkinson’s, such as fatigue, irregular blood pressure, decreased movement of food through the digestive tract, and sudden drop in blood pressure when a person stands up from a sitting or lying-down position.


Parkinson’s symptoms usually begin gradually and get worse over time. As the disease progresses, people may have difficulty walking and talking. They may also have mental and behavioral changes, sleep problems, depression, memory difficulties, and fatigue. According to the National Institute on Aging, Parkinson’s Disease affects both men and women. However, the disease affects about 50% more men than women.


Symptoms of Parkinson’s and the rate of progression differ among individuals. Sometimes people dismiss early symptoms of Parkinson’s like the effects of normal aging. In most cases, there are no medical tests to definitively detect the disease, so it can be difficult to diagnose accurately. Early symptoms of Parkinson’s Disease are subtle and occur gradually. For example, affected people may feel mild tremors or have difficulty getting out of a chair. They may notice that they speak too softly or that their handwriting is slow and looks cramped or small. People with Parkinson’s often develop a parkinsonian gait that includes a tendency to lean forward, small quick steps as if hurrying forward, and reduced swinging of the arms. They also may have trouble initiating or continuing movement. Studies have shown that symptoms of Parkinson’s develop in patients with an 80% or greater loss of dopamine-producing cells in the substantia nigra. As per National Health Services, around one in 500 people are affected by Parkinson’s Disease. Most people with Parkinson’s start to develop symptoms when they’re over 50, although around one in 20 people with the condition first experience symptoms when they’re under 40.


The exact cause of Parkinson’s is unknown. It may have both genetic and environmental components. Low levels of dopamine and norepinephrine, a substance that regulates dopamine, have been linked with Parkinson’s. Abnormal proteins called Lewy bodies have also been found in the brains of people with Parkinson’s. While there is no known cause, research has identified groups of people who are more likely to develop the condition. These include:


  • Sex: Men are one and a half times more likely to get Parkinson’s than women.
  • Race: Whites are more likely to get Parkinson’s than African Americans or Asians.
  • Age: Parkinson’s usually appears between the ages of 50 and 60. It only occurs before the age of 40 in 5–10% of cases.
  • Family history: People who have close family members with Parkinson’s Disease are more likely to develop Parkinson’s Disease, too.
  • Toxins: Exposure to certain toxins may increase the risk of Parkinson’s Disease.
  • Head injury: People who experience head injuries may be more likely to develop Parkinson’s Disease.


Because Parkinson’s Disease develops over time, various stages help identify how symptoms have progressed and what should be expected next. Generally, there are five stages of Parkinson’s Disease:

  • Stage I
  • Stage II
  • Stage III
  • Stage IV
  • Stage V


Although there is currently no cure for Parkinson’s Disease, and treatments are available to help reduce the main symptoms and maintain quality of life for as long as possible. A variety of medicines sometimes help symptoms dramatically. Surgery and deep brain stimulation (DBS) can help in severe cases. With DBS, electrodes are surgically implanted in the brain. They send electrical pulses to stimulate the parts of the brain that control movement.


Parkinson’s Disease Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Parkinson’s Disease market to treat the condition. It also provides the treatment guidelines and algorithms for the United States.


The DelveInsight Parkinson’s Disease market report gives a thorough understanding of Parkinson’s Disease by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. 

Parkinson’s Disease Epidemiology

The Parkinson’s Disease epidemiology division provides insights into the historical and current patient pool along with the forecasted trend for the United States. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.


Key Findings

The disease epidemiology covered in the report provides historical and forecasted Parkinson’s Disease epidemiology segmented as the Total Prevalent Cases of Parkinson’s Disease, Gender-specific Cases of Parkinson’s Disease, Severity-specific Prevalence of Parkinson’s Disease, Age-specific Cases of Parkinson’s Disease, and Prevalent Cases of Parkinson’s Disease based on the onset. The report includes the prevalent scenario of Parkinson’s Disease symptoms in the United States from 2018 to 2030.

United States Parkinson’s Disease Epidemiology

  • The epidemiology segment also provides Parkinson’s Disease epidemiology data and findings across the United States.
  • The total prevalent population of Parkinson’s Disease in the United States was estimated to be 1,073,894 cases in 2020.

Parkinson’s Disease (PD) Drug Chapters

The drug chapter segment of the Parkinson’s Disease report encloses the detailed analysis of Parkinson’s Disease marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps to understand Parkinson’s Disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Since 2014, the US FDA has approved many new Parkinson’s therapies. This momentum is unparalleled in the history of Parkinson’s drug development and a promising sign of biopharmaceutical companies’ are increasing interest and investment in this field.

Products detail in the report…


Parkinson’s Disease Emerging Drugs


Mesdopetam/IRL790 (Integrative Research Laboratories AB) acts by antagonizing the dopamine D3 receptor and thereby counteracting the physiological effects of the signal substance dopamine. The dopamine D3 receptor is genetically linked to increased risk of involuntary movements, and patients with PD-levodopa-induced dyskinesia (LID) have higher amounts of D3 receptors in parts of the brain essential for the control of movements. Mesdopetam has successfully gone through clinical studies demonstrating a good safety and tolerability profile. In 2019, a 28-Day Phase IIa study was concluded evaluating the effect and tolerability of mesdopetam in PD patients exhibiting LIDs. The study results show clinically meaningful and quantitatively impressive effects on dyskinesias as assessed by two of the most used measurements in the field: standardized patient-reported diaries (Hauser diaries) and the Unified Parkinson’s Disease Rating Scale (UPDRS). Patients reported marked improvements without added side effects, demonstrating mesdopetam’s ability to offer a significant qualitative shift in patients’ everyday life.


A larger and longer Phase IIb/III study to further evaluate the effects of mesdopetam in PD-LIDs started in November 2020. The clinical Phase IIb/III study with mesdopetam is a randomized, double-blind, and placebo-controlled study to evaluate the effect of mesdopetam in patients with PD affected by troublesome dyskinesias. Top-line results are expected during the first half of 2022


IPX203 (Amneal Pharmaceuticals) is an investigational extended-release oral capsule formulation of carbidopa and levodopa, being studied as a potential treatment for the symptoms of advanced Parkinson’s Disease. It is designed to have an onset of effect similar to IR CD-LD while providing a longer effect than other oral levodopa products available. The drug is presently being evaluated in two Phase III studies in PD patients.

Products detail in the report…

Parkinson’s Disease Market Outlook

The Parkinson’s Disease market outlook builds a detailed comprehension of the historical, current, and forecasted Parkinson’s Disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.


This segment gives a thorough detail of Parkinson’s Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to clearly view the market at first sight.


According to DelveInsight, Parkinson’s Disease market in the United States is expected to change in the study period 2018–2030.


There are currently no disease-modifying treatments for PD, and management predominantly consists of dopaminergic drugs. The most commonly used of these are preparations of levodopa, the precursor of dopamine, which is administered in combination with a dopa-decarboxylase inhibitor, limiting some of the side effects, such as nausea. Dopamine agonists, such as ropinirole or rotigotine, are also used. Monoamine oxidase B inhibitors, such as rasagiline and selegiline, and catechol-O-methyltransferase (COMT) inhibitors such as entacapone, can be used to reduce the metabolism of endogenous dopamine. These treatments can restore dopaminergic activity in the striatum, heralding improvements in the motor features of PD. However, they do not treat many nonmotor features, which are particularly disabling for many patients. Indeed, in some cases, treatments may exacerbate some of the nonmotor symptoms, such as postural hypotension and neuropsychiatric problems.


Key Findings

This section includes a glimpse of the Parkinson’s Disease market in the US. The market size of Parkinson’s Disease in the United States markets was USD 1390.1 million in 2020.


The United States: Market Outlook

This section provides the total Parkinson’s Disease market size, market size of Parkinson’s Disease by systemic therapies (class-wise), and market size of Parkinson’s Disease by-product in the United States.


The approved medication therapies are categorized into seven groups that include levodopa, carbidopa-levodopa infusion (Duodopa), dopamine agonists (Mirapex, Requip, Neupro), MAO B inhibitors (Zelapar, Azilect, Xadago), catechol o-methyltransferase (COMT) inhibitors (Tasmar, Comtan), anticholinergics (Cogentin, Artane), adenosine A2a antagonists (Istradefylline) and amantadine (Gocovri, OSMOLEX ER). The treatment is given based on the stages of the disease, symptoms shown, and those who are already receiving some medication. Based on the mentioned criteria the treatment can be classified into early-stage, late-stage, and nonmotor symptoms.


Neurocrine’s oral compound Ongentys (opicapone)—approved by the FDA in April 2020—and Sunovion’s thin-film formulation of apomorphine (approved in May 2020) help control symptoms during “off” times, when the gold standard medication levodopa (Sinemet) fails, and Parkinson’s symptoms relapses each day. Apomorphine can quickly relieve symptoms when levodopa wears off but must be delivered via injection. However, Sunovion has developed a new delivery method and option for those who prefer it over an injection approach — Kynmobi, a thin-film formulation that can be placed under the tongue.


The crop of recently approved treatments includes other medications (e.g., inhaled levodopa [Inbrija] and istradefylline [Nourianz]) to ease “off” time along with treatments for psychosis, excessive salivation/drooling, and sudden drops in blood pressure. These therapies for nonmovement aspects of Parkinson’s are filling longstanding gaps in care and helping patients live better with Parkinson’s.

Parkinson’s Disease Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Parkinson’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Parkinson’s Disease Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses Parkinson’s Disease key players involved in developing targeted therapeutics.


Major players include Addex Pharma, Annovis Bio Inc, Pharma Two B Ltd, AbbVie, Prevail Therapeutics, Axovant Gene Therapies, Denali Therapeutics, Neurocrine Biosciences, and others, whose key products are expected to get launched in the US market by 20XX.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Parkinson’s Disease emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinions working in the Parkinson’s Disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Parkinson’s Disease market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Parkinson’s Disease market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Parkinson’s Disease, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Parkinson’s Disease epidemiology and treatment in the United States.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Parkinson’s Disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Parkinson’s Disease market; historical and forecasted, is included in the report, covering drug outreach in the United States.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Parkinson’s Disease market.

Report Highlights

  • In the coming years, the Parkinson’s Disease market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Parkinson’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Parkinson’s Disease. The launch of emerging therapies will significantly impact the Parkinson’s Disease market
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Parkinson’s Disease.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Parkinson’s Disease Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Parkinson’s Disease Pipeline Analysis
  • Parkinson’s Disease Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Parkinson’s Disease Report Key Strengths

  • 10-years Forecast
  • The United States Coverage
  • Parkinson’s Disease Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Parkinson’s Disease Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Parkinson’s Disease Market share (%) distribution in 2018, and how would it look like in 2030?
  • What would be the Parkinson’s Disease total market size and market size by therapies in the United States during the forecast period (2018–2030)?
  • What are the key findings pertaining to the market across the United States during the forecast period (2018–2030)?
  • At what CAGR, the Parkinson’s Disease market is expected to grow in the United States during the forecast period (2018–2030)?
  • What would be the Parkinson’s Disease market outlook across the United States during the forecast period (2018–2030)?
  • What would be the Parkinson’s Disease market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Parkinson’s Disease?
  • What is the historical Parkinson’s Disease patient pool in the United States?
  • What would be the forecasted patient pool of Parkinson’s Disease in the United States?
  • What will be the growth opportunities in the United States with respect to the patient population pertaining to Parkinson’s Disease?
  • At what CAGR the population is expected to grow in the United States during the forecast period (2018–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Parkinson’s Disease?
  • What are the current treatment guidelines for treating Parkinson’s Disease in the United States?
  • What are the Parkinson’s Disease marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Parkinson’s Disease?
  • How many therapies are developed by each company for the treatment of Parkinson’s Disease?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Parkinson’s Disease?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to Parkinson’s Disease therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Parkinson’s Disease and its status?
  • What are the key designations that have been granted for the emerging therapies for Parkinson’s Disease?
  • What are the global historical and forecasted markets for Parkinson’s Disease?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Parkinson’s Disease market
  • To understand the future market competition in the Parkinson’s Disease market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Parkinson’s Disease in the United States.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Parkinson’s Disease market.
  • To understand the future market competition in the Parkinson’s Disease market.

1. Key Insights

2. Report Introduction

3. Executive Summary of Parkinson’s Disease

4. Disease Background and Overview

4.1. Introduction

4.2. Cause of Parkinson’s Disease

4.3. Signs and Symptoms of Parkinson’s Disease

4.3.1. Motor Symptoms

4.3.2. Nonmotor Symptoms

4.3.3. Physical symptoms

4.3.4. Cognitive and psychiatric symptoms

4.4. Stages of Parkinson’s Disease

4.5. Risk Factors for Parkinson’s Disease

4.5.1. Gender

4.5.2. Age

4.5.3. Ethnicity

4.5.4. Family History and Genetics

4.5.5. Head Trauma

4.5.6. Environmental Pesticides

4.6. Classification of Parkinson’s Disease

4.6.1. Juvenile Parkinson Disease

4.6.2. Young-onset Parkinson’s Disease

4.6.3. Idiopathic Parkinson Disease or Classic Parkinson Disease

4.7. Genetics of Parkinson’s Disease

4.7.1. Autosomal dominant Parkinson’s Disease genes

4.7.2. Autosomal recessive Parkinson’s Disease genes

4.7.3. Autosomal recessive genes causing Parkinsonism with atypical features

4.7.4. Autosomal dominant genes and loci with unclear pathogenicity

4.8. Pathophysiology

4.8.1. The Role of Dopamine

4.8.2. Lewy Bodies and Alpha-Synuclein

4.8.3. Inflammation and Immune Response

4.9. Diagnosis

4.9.1. CT (Computerized Tomography) scan

4.9.2. MRI (Magnetic Resonance Imaging) scan

4.9.3. DaTSCAN-SPECT scan

4.9.4. PET (Positron Emission Tomography) scan

4.9.5. The importance of early diagnosis

4.9.6. Diagnostic Guidelines

4.9.7. Diagnostic Algorithm

4.10. Treatment and Management

4.10.1. Carbidopa-levodopa

4.10.2. Carbidopa-levodopa infusion

4.10.3. Dopamine agonists

4.10.4. Monoamine oxidase B (MAO B) inhibitors

4.10.5. Catechol O-methyltransferase (COMT) inhibitors

4.10.6. Anticholinergics

4.10.7. Amantadine

4.11. Treatment algorithm

4.12. Treatment Guidelines

4.12.1. National Institute for Health and Care Excellence (NICE): Recommendation for Parkinson’s Disease

4.12.2. EFNS/MDS-ES recommendations on therapeutic management of Parkinson’s Disease 2010

4.12.3. American Academy of Family Physicians: Recommendations for Treatment of Parkinson’s Disease

4.12.4. American Academy of Neurology (ANN): Parkinson’s Disease Quality Measurement Set Update

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Epidemiology of Parkinson’s Disease

5.3. The United States

5.3.1. Total Prevalent Population of Parkinson’s Disease (PD) in the United States

5.3.2. Gender-specific Prevalent Population of Parkinson’s Disease (PD) in the United States

5.3.3. Age-specific Prevalent Population of Parkinson’s Disease (PD) in the United States

5.3.4. Prevalent Population of Parkinson’s Disease (PD) based on Onset in the United States

5.3.5. Stage-specific Prevalence of Parkinson’s Disease (PD) in the United States

6. Organizations contributing toward Parkinson’s Disease

7. Patient Journey

8. Case Reports

9. Marketed Products

9.1. Key cross competition

9.2. KYNMOBI: Sunovion Pharmaceuticals

9.2.1. Product Description

9.2.2. Regulatory Milestone

9.2.3. Other developmental activities

9.2.4. Safety and Efficacy

9.2.5. Side Effects

9.2.6. Product Profile

9.3. Gocovri: Adamas Pharmaceuticals

9.3.1. Product Description

9.3.2. Regulatory Milestone

9.3.3. Other developmental activities

9.3.4. Safety and Efficacy

9.3.5. Side Effects

9.3.6. Product Profile

9.4. Ongentys: Neurocrine Biosciences

9.4.1. Product Description

9.4.2. Regulatory Milestone

9.4.3. Other Developmental Activities

9.4.4. Safety and Efficacy

9.4.5. Side Effects

9.4.6. Product Profile

9.5. OSMOLEX ER: Adamas Pharmaceutical

9.5.1. Product Description

9.5.2. Regulatory Milestone

9.5.3. Other Developmental Activities

9.5.4. Safety and Efficacy

9.5.5. Side Effects

9.5.6. Product Profile

9.6. Xadago: Supernus Pharmaceuticals

9.6.1. Product Description

9.6.2. Regulatory Milestone

9.6.3. Other Development Activities

9.6.4. Safety and Efficacy

9.6.5. Side Effects

9.6.6. Product Profile

9.7. Nourianz: Kyowa Kirin

9.7.1. Product Description

9.7.2. Regulatory Milestone

9.7.3. Safety and Efficacy

9.7.4. Side Effects

9.7.5. Product Profile

9.8. Duopa: AbbVie

9.8.1. Product Description

9.8.2. Regulatory Milestone

9.8.3. Other Developmental Activities

9.8.4. Safety and Efficacy

9.8.5. Side Effects

9.8.6. Product Profile

10. Emerging Therapies

10.1. Key Cross of Emerging Drugs

10.2. Mesdopetam: Integrative Research Laboratories AB

10.2.1. Drug Description

10.2.2. Other development activities

10.2.3. Clinical Development

10.2.4. Safety and Efficacy

10.2.5. Product Profile

10.3. Posiphen: Annovis Bio Inc.

10.3.1. Drug Description

10.3.2. Other Development Activities

10.3.3. Clinical Development

10.3.4. Product Profile

10.4. Tavapadon (CVL-751/PF-06649751): Cerevel Therapeutics

10.4.1. Drug Description

10.4.2. Other Development Activities

10.4.3. Clinical Development

10.4.4. Safety and Efficacy

10.4.5. Product Profile

10.5. IPX203: Amneal Pharmaceuticals

10.5.1. Drug Description

10.5.2. Other Development Activities

10.5.3. Clinical Development

10.5.4. Safety and Efficacy

10.5.5. Product Profile

10.6. P2B001: Pharma Two B

10.6.1. Drug Description

10.6.2. Clinical Development

10.6.3. Safety and Efficacy

10.6.4. Product Profile

10.7. ABBV-951: AbbVie

10.7.1. Drug Description

10.7.2. Other Development Activities

10.7.3. Clinical Development

10.7.4. Safety and Efficacy

10.7.5. Product Profile

10.8. Dipraglurant: Addex Pharma S.A.

10.8.1. Drug Description

10.8.2. Other Development Activities

10.8.3. Clinical Development

10.8.4. Safety and Efficacy

10.8.5. Product Profile

10.9. ND0612: Mitsubishi Tanabe Pharma

10.9.1. Drug Description

10.9.2. Other Development Activities

10.9.3. Clinical Development

10.9.4. Safety and Efficacy

10.9.5. Product Profile

10.10. SPN-830: Supernus Pharmaceuticals

10.10.1. Drug Description

10.10.2. Other Developmental Activities

10.10.3. Clinical Development

10.10.4. Safety and Efficacy

10.10.5. Product Profile

10.11. Other Promising Therapies

10.12. Other Assets in Development

10.13. VY-AADC: Voyager Therapeutics

10.13.1. Drug Description

10.13.2. Other Development Activities

10.13.3. Clinical Development

10.13.4. Product Profile

10.14. Liraglutide: Novo Nordisk

10.14.1. Drug Description

10.14.2. Clinical Development

10.14.3. Product Profile

10.15. NYX-458: Aptinyx

10.15.1. Drug Description

10.15.2. Other Developmental Activities

10.15.3. Clinical Development

10.15.4. Safety and Efficacy

10.15.5. Safety and Efficacy

10.15.6. Product Profile

10.16. SEP-363856: Sunovion/PsychoGenics

10.16.1. Drug Description

10.16.2. Other Development Activities

10.16.3. Clinical Development

10.16.4. Product Profile

10.17. GRF6021: Alkahest/Grifols

10.17.1. Drug Description

10.17.2. Other Developmental Activities

10.17.3. Clinical Development

10.17.4. Safety and Efficacy

10.17.5. Product Profile

10.18. Lenrispodun: Intracellular Therapies

10.18.1. Drug Description

10.18.2. Other Development Activity

10.18.3. Clinical Development

10.18.4. Safety and Efficacy

10.18.5. Product Profile

10.19. PROO1A: Eli Lilly and Company

10.19.1. Drug Description

10.19.2. Other Development Activities

10.19.3. Clinical Development

10.19.4. Product Profile

10.20. Lazucirnon: Alkahest/Grifols

10.20.1. Drug Description

10.20.2. Other development activities

10.20.3. Clinical Development

10.20.4. Product Profile

10.21. ATH-1017: Athira Pharma

10.21.1. Drug Description

10.21.2. Clinical Development

10.21.3. Product Profile

10.22. TAK-071: Takeda

10.22.1. Drug Description

10.22.2. Clinical Development

10.22.3. Product Profile

10.23. AV-101: VistaGen Therapeutics

10.23.1. Drug Description

10.23.2. Other Development activities

10.23.3. Clinical Development

10.23.4. Product Profile

10.24. E2027: Eisai Inc.

10.24.1. Drug Description

10.24.2. Clinical Development

10.24.3. Product Profile

10.25. UCB0599: UCB Biopharma

10.25.1. Drug Description

10.25.2. Other Development Activity

10.25.3. Clinical Development

10.25.4. Safety and Efficacy

10.25.5. Product Profile

10.26. NLY01: Neuraly

10.26.1. Drug Description

10.26.2. Other Developmental Activities

10.26.3. Clinical Development

10.26.4. Safety and Efficacy

10.26.5. Product Profile

10.27. SAGE-718: Sage Therapeutics

10.27.1. Product Description

10.27.2. Clinical Development

10.27.3. Safety and Efficacy

10.27.4. Product Profile

10.28. SCC-138/ K0706: Sun Pharma Advanced Research Company (SPARC)

10.28.1. Product Description

10.28.2. Clinical Development

10.28.3. Product Profile

10.29. Kenterin: Enterin

10.29.1. Drug Description

10.29.2. Clinical Development

10.29.3. Safety and Efficacy

10.29.4. Product Profile

10.30. Prasinezumab: Hoffmann-La Roche/Prothena Biosciences Limited

10.30.1. Drug Description

10.30.2. Other Developmental Activities

10.30.3. Clinical Development

10.30.4. Safety and Efficacy

10.30.5. Product Profile

10.31. THN102: Theranexus

10.31.1. Drug Description

10.31.2. Other Developmental Activities

10.31.3. Clinical Development

10.31.4. Safety and Efficacy

10.31.5. Product Profile

10.32. JM-010/Buspirone/Zolmitriptan: Bukwang Pharmaceutical

10.32.1. Drug Description

10.32.2. Other Developmental Activities

10.32.3. Clinical Development

10.32.4. Product Profile

10.33. CVN424: Cerevance Beta

10.33.1. Drug Description

10.33.2. Other Developmental Activities

10.33.3. Clinical Development

10.33.4. Safety and Efficacy

10.33.5. Product Profile

11. Parkinson’s Disease: the US Market Analysis

11.1. Key Findings

11.2. Market Outlook

11.3. The United States Market Size

11.3.1. Total Market Size of Parkinson’s Disease in The United States

11.3.2. Total Market Size of Parkinson’s Disease by Therapies in The United States

11.3.3. Total Market Size of Parkinson’s Disease by Approved Therapies in The United States

11.3.4. Total Market Size of Parkinson’s Disease by Emerging Therapies in The United States

12. KOL Views

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. Appendix

17.1. Bibliography

17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Table

Table 1: Summary of Parkinson’s Disease, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Signs and Symptoms of Parkinson’s Disease

Table 3: Differential Diagnosis of Parkinsonism

Table 4: Formulations and key precautions for first-line drugs to treat Parkinson’s Disease

Table 5: Potential benefits and harms of dopamine agonists, levodopa, and MAO B inhibitors

Table 6: Potential benefits and harms of dopamine agonists, levodopa, and MAO B inhibitors

Table 7: Pharmacological management of Non-motor Symptoms

Table 8: Nonpharmacological management of motor and nonmotor symptoms

Table 9: Practical recommendations for the treatment of early untreated PD

Table 10: Practical recommendations for the adjustment of initial therapy in patients without motor complications

Table 11: Practical recommendations for the treatment of early untreated PD

Table 12: Key Recommendations for the treatment of Parkinson’s Disease

Table 13: Total Prevalent Population of Parkinson’s Disease (PD) in the United States (2018–2030)

Table 14: Gender-specific Prevalent Population of Parkinson’s Disease (PD) in the United States (2018–2030)

Table 15: Age-specific Prevalent Population of Parkinson’s Disease (PD) in the United States (2018–2030)

Table 16: Prevalent Population of Parkinson’s Disease (PD) based on onset in the United States (2018–2030)

Table 17: Stage-specific Prevalence of Parkinson’s Disease (PD) in the United States (2018–2030)

Table 18: Organizations contributing towards Parkinson’s Disease

Table 19: Key cross of the Marketed drugs

Table 20: Mesdopetam, Clinical Trial Description, 2021

Table 21: Posiphen, Clinical Trial Description, 2021

Table 22: Tavapadon, Clinical Trial Description, 2021

Table 23: IPX203, Clinical Trial Description, 2021

Table 24: PB2001, Clinical Trial Description, 2021

Table 25: ABBV-951, Clinical Trial Description, 2021

Table 26: Dipraglurant, Clinical Trial Description, 2021

Table 27: ND0612, Clinical Trial Description, 2021

Table 28: VY-AADC, Clinical Trial Description, 2021

Table 29: Liraglutide, Clinical Trial Description, 2021

Table 30: NYX-458, Clinical Trial Description, 2021

Table 31: SEP-363856, Clinical Trial Description, 2021

Table 32: GRF6021, Clinical Trial Description, 2021

Table 33: Lenrispodun, Clinical Trial Description, 2021

Table 34: PROO1A, Clinical Trial Description, 2021

Table 35: AKST4290, Clinical Trial Description, 2021

Table 36: ATH-1017, Clinical Trial Description, 2021

Table 37: TAK-071, Clinical Trial Description, 2021

Table 38: AV-101, Clinical Trial Description, 2021

Table 39: E2027, Clinical Trial Description, 2021

Table 40: UCB0599, Clinical Trial Description, 2021

Table 41: NLY01, Clinical Trial Description, 2021

Table 42: SAGE-718, Clinical Trial Description, 2021

Table 43: K0706; Clinical Trial Description, 2021

Table 44: Apomorphine infusion; Clinical Trial Description, 2021

Table 45: Prasinezumab (PRX002/RO7046015/ RG7935); Clinical Trial Description, 2021

Table 46: THN102, Clinical Trial Description, 2021

Table 47: JM-101, Clinical Trial Description, 2021

Table 48: CVN424 Clinical Trial Description, 2021

Table 49: The United States Market Size of Parkinson’s Disease in USD Million (2018–2030)

Table 50: The United States Market Size of Parkinson’s Disease by Therapies in USD Million (2018–2030)

Table 51: The United States Market Size of Parkinson’s Disease by Approved Therapies in USD Million (2018–2030)

Table 52: The United States Market Size of Parkinson’s Disease by Emerging Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Causes of Parkinson’s Disease

Figure 2: Stages of Parkinson’s disease

Figure 3: Causes of Parkinson’s disease

Figure 4: Risk Factors for Parkinson’s Disease

Figure 5: Types of Parkinson Disease

Figure 6: Dopamine level in a normal and Parkinson’s affected neuron

Figure 7: Pathways to Parkinson’s Disease

Figure 8: Queen Square Brain Bank UK PDS Brain Bank Criteria for the diagnosis of PD

Figure 9: Diagnosis and Management of Parkinson’s Disease

Figure 10: Pharmacologic Treatment options available for Parkinson’s disease

Figure 11: Algorithm for medical treatment of Parkinson’s disease

Figure 12: Treatment guidelines for the progressive stages of Parkinson’s disease

Figure 13: Total Prevalent Population of Parkinson’s Disease (PD) in the US (2018–2030)

Figure 14: Gender-specific Prevalent Population of Parkinson’s Disease (PD) in the United States (2018–2030)

Figure 15: Age-specific Prevalent Population of Parkinson’s Disease (PD) in the United States (2018–2030)

Figure 16: Prevalent Population of Parkinson’s Disease (PD) based on onset in the US (2018–2030)

Figure 17: Stage-specific Prevalence of Parkinson’s Disease (PD) in the United States (2018–2030)

Figure 18: Market Size of Parkinson’s Disease in the United States, USD Million (2018–2030)

Figure 19: The United States Market Size of Parkinson’s Disease by Therapies in USD Million

Figure 20: The United States Market Size of Parkinson’s Disease by Approved Therapies in USD Million (2018–2030)

Figure 21: The United States Market Size of Parkinson’s Disease by Emerging Therapies in USD Million (2018–2030)

• Sunovion Pharmaceuticals

• Adamas Pharmaceuticals

• Neurocrine Biosciences

• Adamas Pharmaceutical

• Supernus Pharmaceuticals

• Kyowa Kirin

• AbbVie

• Integrative Research Laboratories AB

• Annovis Bio Inc.

• Cerevel Therapeutics

• Amneal Pharmaceuticals

• Pharma Two B

• AbbVie

• Addex Pharma S.A.

• Mitsubishi Tanabe Pharma

• Supernus Pharmaceuticals

• Voyager Therapeutics

• Novo Nordisk

• Aptinyx

• Sunovion/PsychoGenics

• Alkahest/Grifols

• Intracellular Therapies

• Eli Lilly and Company

• Alkahest/Grifols

• Athira Pharma

• Takeda

• VistaGen Therapeutics

• Eisai Inc.

• UCB Biopharma

• Neuraly

• Sage Therapeutics

• Sun Pharma Advanced Research Company (SPARC)

• Enterin

• Hoffmann-La Roche/Prothena Biosciences Limited

• Theranexus

• Bukwang Pharmaceutical

• Cerevance Beta

  • Tags:
  • Parkinson's Disease market
  • Parkinson's Disease market researc...
  • Parkinson's Disease market insight
  • Parkinson's Disease market trends
  • Parkinson's Disease market forecas...
  • Parkinson's Disease market share
  • Parkinson's Disease pipeline drugs
  • Parkinson's Disease treatment algo...
  • Parkinson's Disease drugs
  • Parkinson's Disease sales forecast...
  • Parkinson's Disease market size
  • Parkinson's Disease disease
  • Parkinson's Disease epidemiology
  • Parkinson's Disease

Forward to Friend

Need A Quote